A Patient with KL-6 Elevation with Anti-TNFα Who Could Receive Long-Term Use without Interstitial Pneumonia after Class Switch of Anti-TNFα-Reference-Cited by-同舟云学术

A Patient with KL-6 Elevation with Anti-TNFα Who Could Receive Long-Term Use without Interstitial Pneumonia after Class Switch of Anti-TNFα

Published:2019 Issue:1 Volume:4 Page:35-40
ISSN:2296-9403
Container-title:Inflammatory Intestinal Diseases
language:en
Short-container-title:Inflamm Intest Dis

Author:

Masuda Takuya,Yoshida Atsushi,Ueno Fumiaki,Hara Shintaro,Nabeta Haruaki,Umezawa Shotaro,Shirai Mayuki,Morikawa Yoshihide,Morizane Toshio,Endo Yutaka,Hibi Toshifumi

Publisher

S. Karger AG

Subject

Gastroenterology

Reference29 articles.

1. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr;106(4):644–59.

2. Khasnis AA, Calabrese LH. Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk. Semin Arthritis Rheum. 2010 Oct;40(2):147–63.

3. Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, Pego-Reigosa JM, Retamozo S, Bove A, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum. 2011 Oct;41(2):256–64.

4. Rofaiel R, Kohli S, Mura M, Hosseini-Moghaddam SM. A 53-year-old man with dyspnoea, respiratory failure, consistent with infliximab-induced acute interstitial pneumonitis after an accelerated induction dosing schedule. BMJ Case Rep. 2017 May;2017:12.

5. Numakura T, Tamada T, Nara M, Muramatsu S, Murakami K, Kikuchi T, et al. Simultaneous development of sarcoidosis and cutaneous vasculitis in a patient with refractory Crohn’s disease during infliximab therapy. BMC Pulm Med. 2016 Feb;16(1):30.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adalimumab/infliximab;Reactions Weekly;2019-06